|
|
|
LifeScienceHistory.com - Check us out on Instagram
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Madrigal Pharmaceuticals, Inc.
| | | Phone: | (781) 274-8200 | Fax: | (781) 274-8228 | Year Established: | 1997 | Employees: | 130 | Ticker: | SNTA | Exchange: | NASDAQ | Main Contact: | Paul A. Friedman, M.D., Chairman & CEO | | Other Contacts: | Marc Schneebaum, CFO Rebecca Taub, M.D., CMO & Executive VP, R&D
| | Company Description | Madrigal Pharmaceuticals, formerly Synta Pharmaceuticals, is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead candidate, MGL-3196, is an orally administered, small-molecule liver-directed ß-selective THR agonist with high liver uptake for the treatment of NASH and dyslipidemia/hypercholesterolemia including in heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH). | |
|
|
|
|
|